Clinical trials: Genital Infection
Human Immunodeficiency Virus
A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
The CABOTEGRAVIR Long Acting + RILPIVIRENE Long Acting regimen was currently endorsed by guidelines worldwide as an option for the Treatment of HIV-1 Infection, however collecting real-world data closer to clinical practice use…
- Trial name
- CABO-CHANCE (NCT06518408)
- Testing
- Cabotegravir Injectable Product, Rilpivirine Injectable Product
- Where
- 15 sites in Spain
- Volunteers
- 287 people
- Sponsor
- University Hospital Virgen de las Nieves
HIV, Substance Abuse
Young Women's Health CoOp (Cooperative) in Cape Town
This supplement study is an adaptation of the larger NIH-funded parent study, the Women's Health CoOp+, which tests a combination biobehavioral HIV prevention approach to enhance standard HIV testing practices for alcohol and…
- Trial name
- YWHC (NCT02677025)
- Testing
- Young Women's Health CoOp (YWHC), HIV Counseling/Testing
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- RTI International
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
Acquired Immunodeficiency Syndrome, Blood Transfusion
HIV Diversity and Pathogenesis in Donor-Recipient Clusters
To assess, in donor-recipient clusters, current models of HIV-1 genetic evolution and pathogenesis, based on the sequence diversity displayed by this lentivirus.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Transfusion, Blood Donors, HIV Infections
- Trial name
- NCT00005360
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Human Papillomavirus Infection
Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly…
- Trial name
- NCT06281119
- Testing
- Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
- Where
- 4 sites in Kenya, Mozambique and 1 more
- Volunteers
- 450 people
- Sponsor
- Serum Institute of India Pvt. Ltd.
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Hiv, HBV Coinfection
Towards a Functional Cure for HBV - The COMMIT Cohort Study
Hepatitis B virus (HBV) infection can be treated, but therapy is usually lifelong and has side effects, so a cure for HBV is a critical endpoint.
- Trial name
- COMMIT (NCT03645044)
- Where
- 3 sites in India, Malaysia and 1 more
- Volunteers
- 102 people
- Sponsor
- University of Melbourne
Substance Use Disorders, Hiv
Open Trial to Improve Retention in Care for Persons With HIV Who Use Substances
The open trial will examine the feasibility and acceptability of a brief, empirically-supported acceptance-based behavioral therapy intervention to promote retention in care for out-of-care people with HIV who use substances.
- Trial name
- NCT05101044
- Testing
- Acceptance-based Behavioral Therapy (ABBT) Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Brown University
HIV Infections
Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
The purpose of this study is to see if different doses of an experimental HIV vaccine are safe and to study how the immune system responds to the vaccine. The vaccine will be tested in healthy, HIV uninfected volunteers.
- Trial name
- NCT00063778
- Testing
- AVX101
- Where
- 7 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
Hiv
Exploring a Digital HIV Onward Disclosure Intervention, in People Living With HIV of Sub-Saharan African Ethnicity.
Research has shown that people living with HIV struggle to disclose their HIV status to others, (a process known as self-disclosure or onward disclosure) due to associated challenges, including fear of discrimination from others.
- Trial name
- NCT05804968
- Testing
- Digital HIV Self Disclosure Intervention
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Royal Holloway University
In Utero Drug Exposure
Cardiometabolic Health of Children Exposed to Anti-retroviral Therapy (ART) in Utero
The Human Immunodeficiency Virus (HIV) has been recently linked to increased risk for cardiovascular diseases (CVDs). The prevalence of cardiovascular diseases and its risk factor, hypertension, are very high in African…
- Trial name
- ARTMOMSBABES (NCT04763668)
- Testing
- Pregnant HIV positive women on ARTs, Babies born to HIV positive mothers on ARTs
- Where
- South Africa
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Walter Sisulu University
HIV Infections
Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term
The summary of the Study is to compare two methods in order to predict how the 1-HIV will use a co-receptor: the use of an accredited test (TROFILE ESTA®) and the viral response to a CCR5 antagonist in the short term.
- Trial name
- TROPISMVC (NCT01060618)
- Testing
- Maraviroc + Trofile ESTA® (diagnose test)
- Where
- 4 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
HIV Infections, Hepatitis B
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking…
- Trial name
- NCT00051090
- Testing
- Telbivudine, Lamivudine, Efavirenz
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome
Longitudinal Study of HAART, Social Networks, & Adherence
Our study is a randomized controlled trial that aims to evaluate the effectiveness of modified directly observed therapy (mDOT) to (1) increase both short and long term adherence to HAART treatment, and (2) improve clinical…
- Trial name
- NCT00272220
- Testing
- modified directly observed therapy (mDOT)
- Where
- Mozambique
- Volunteers
- 350 people
- Sponsor
- University of Washington
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
HIV Infection
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
This study uses autologous (one's own) CD4 T cells modified with a viral vector expressing a genetic antisense targeting HIV, this vector is called VRX496.
- Trial name
- NCT00131560
- Testing
- VRX496-Modified Autologous T cells
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- VIRxSYS Corporation
HIV/AIDS, Mental Health Issue
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
The investigative team will conduct a 2-arm randomized control trial to examine the preliminary effect of LinkPositively+ (LPP) an enhanced version of LinkPositively (LP) mobile app on improved HIV care outcomes including…
- Trial name
- LPP Plus (NCT06458660)
- Testing
- LPP+: Mindfulness Meditation Delivered, LP
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Guiding Right, Inc.
HIV Infections
Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine
Summary: Chloroquine is a medication that in laboratory settings has significant anti-HIV effects in HIV infected T-cells. Chloroquine has been used safely for over 60 years for malaria treatment and prevention, and it also has…
- Trial name
- NCT00308620
- Testing
- chloroquine phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Minnesota
HIV Infections
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
The purpose of the study is to determine the safety of and immune response to the investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.
- Trial name
- NCT00141024
- Testing
- EP HIV-1043, EP HIV-1090
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.